Notícias e Atividades da Acadia Pharmaceuticals

Acadia Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Acadia Pharmaceuticals é uma empresa listada sob o símbolo ACAD (US).

Veja o organograma con seus 40 executivos principais

Biografias mais buscadas da Acadia Pharmaceuticals

• Catherine Owen, Chief Executive Officer and Director
• Laura Brege, Director
• Edmund Harrigan, Director

Recentes movimentos de executivos em Acadia Pharmaceuticals

• Thomas Garner, ingressou na Companhia como Chief Commercial Officer  (Notícia publicada em 10 de dezembro de 2024).
• Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial, deixará a Companhia em 31 de dez. de 2024  (Notícia publicada em 22 de novembro de 2024).
• Catherine Owen, ingressou na Companhia como Chief Executive Officer and Director  (Notícia publicada em 24 de setembro de 2024).

Clique aqui para ver outras movimentos em Acadia Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Acadia Pharmaceuticals.

Acadia Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Acadia Pharmaceuticals

• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
• Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
• Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
• Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
• Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• View more press releases Close

Redes sociais sobre Acadia Pharmaceuticals

• Acadia Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Acadia Pharmaceuticals na LinkedIn, Twitter e YouTube